Article Text


SAT0085 Meloxicam has a low risk of serious gastrointestinal complications: pooled analysis of 27,039 patients
  1. G Singh1,
  2. G Triadafilopoulos2
  1. 1Medicine/Immunology and Rheumatology, Stanford University Medical Center
  2. 2Section of Gastroenterology, Palo Alto Veterans Affairs Health Care System, Palo Alto, USA


Background Gastrointestinal (GI) complications are the most common adverse events associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Although serious gastrointestinal complications, such as perforated ulcers and catastrophic bleeding, are uncommon, these events area.

Objectives We reviewed the incidence of serious upper GI (UGI) complications, including perforations, obstructions and hemodynamically-significant bleeds in a pooled data analysis of Meloxicam clinical trials that were at least 3 weeks in duration and included at least 20 patients per arm.

Methods Thirty-five trials with 27,309 patients on Meloxicam, comparator NSAID?s, or placebo were included in the analysis. Nearly 39% (8109) patients were over age 65, and 1002 patients (4%) had a previous history of perforation, ulcer or bleed. Cases of suspected GI events were ascertained based on pre-defined criteria. Case report forms and supporting details were blinded and submitted to an independent Endpoint Committee for adjudication.

Results A total of 448 potential cases were identified and sent for adjudication. The Endpoint Committee determined that 54 of these cases met the predefined criteria for a clinically significant event.

Abstract SAT0085 Table 1

Conclusion The risk of clinically significant UGI events with meloxicam is dose-dependent and low at the recommended doses of 7.5 mg and 15 mg.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.